Work

Pyrotinib plus nab-paclitaxel as adjuvant therapy for patients with N0/N1mi, HER2-positive early-stage breast cancer: 3-year iDFS results of the phase II PHAEDRA trial.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.533

Authors: Changjun Wang, Ying Xu, Yan Lin, Feng Mao, Jinghong Guan, Songjie Shen, Yanna Zhang, Xiaohui Zhang, Xuejing Wang, Ying Zhong, Bo Pan, Yan Li, Xin Huang, Li Peng, Xi Cao, Ru Yao, Jie Lang, Yidong Zhou, Qiang Sun

Institution: Peking Union Medical College Hospital

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162542685

Cites:

Cited by: 1

Related to: